A drug-drug interaction study of CT-1812 in U.S. patients with Alzheimer's disease.

Trial Profile

A drug-drug interaction study of CT-1812 in U.S. patients with Alzheimer's disease.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs CT 1812 (Primary) ; Dextromethorphan; Midazolam; Omeprazole; Tolbutamide
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jul 2017 According to a Cognition Therapeutics media release, results will be discussed at the Canaccord Genuity Conference.
    • 19 Jul 2017 Status changed from recruiting to active, no longer recruiting according to a Cognition Therapeutics media release.
    • 19 Jul 2017 According to a Cognition Therapeutics media release, results from this trial were presented at the Alzheimer's Association International Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top